VF
DNA icon

Virtu Financial’s Ginkgo Bioworks DNA Stock Holding History

Virtu Financial’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,149
Closed -$146K – 1430
2024
Q1 		$146K Sell
3,149
-1,810
-36% -$93.7K 0.01% 856
2023
Q4 		$335K Sell
4,959
-4,434
-47% -$272K 0.03% 562
2023
Q3 		$680K Buy
+9,393
New +$751K 0.07% 266
2023
Q2 		– Sell
-11,129
Closed -$592K – 1624
2023
Q1 		$592K Buy
11,129
+10,471
+1,591% +$664K 0.06% 298
2022
Q4 		$44K Sell
658
-2,560
-80% -$235K 0.01% 1106
2022
Q3 		$402K Sell
3,218
-7,546
-70% -$899K 0.04% 499
2022
Q2 		$1.02M Buy
+10,764
New +$1.31M 0.09% 219
2022
Q1 		– Sell
-2,174
Closed -$722K – 1617
2021
Q4 		$722K Sell
2,174
-1,304
-37% -$619K 0.07% 255
2021
Q3 		$1.61M Buy
+3,478
New +$1.69M 0.14% 128

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Virtu Financial's DNA Position: Q2 2024 in Review

Virtu Financial sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 3,149 shares — an estimated $146K sold.

Virtu Financial first reported a position in DNA in Q3 2021 and held it in 9 quarters. The position peaked at $1.61M in Q3 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Virtu Financial reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Virtu Financial sold 3,149 Ginkgo Bioworks shares in Q2 2024, an estimated $146K.
  • Virtu Financial first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 9 quarters.
  • Virtu Financial's Ginkgo Bioworks position peaked at $1.61M in Q3 2021.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.